ERBB2 and breast carcinoma: Furthermore, knockdown of STEAP4 also suppressed cell proliferation and enhanced the pharmacological effect of lapatinib (HER2 inhibitor) in HER2-overexpressing breast cancer [45], confirming its potential oncogenic role in breast cancer.